These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 29405062)

  • 1. Cerasomal Lovastatin Nanohybrids for Efficient Inhibition of Triple-Negative Breast Cancer Stem Cells To Improve Therapeutic Efficacy.
    Song L; Tao X; Lin L; Chen C; Yao H; He G; Zou G; Cao Z; Yan S; Lu L; Yi H; Wu D; Tan S; Ouyang W; Dai Z; Deng X
    ACS Appl Mater Interfaces; 2018 Feb; 10(8):7022-7030. PubMed ID: 29405062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lovastatin Inhibits EMT and Metastasis of Triple-Negative Breast Cancer Stem Cells Through Dysregulation of Cytoskeleton-Associated Proteins.
    Zheng C; Yan S; Lu L; Yao H; He G; Chen S; Li Y; Peng X; Cheng Z; Wu M; Zhang Q; Li G; Fu S; Deng X
    Front Oncol; 2021; 11():656687. PubMed ID: 34150623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
    Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
    FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
    Liu J; Chen X; Ward T; Pegram M; Shen K
    Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.
    Xu X; Zhang L; He X; Zhang P; Sun C; Xu X; Lu Y; Li F
    Biochem Biophys Res Commun; 2018 Jul; 502(1):160-165. PubMed ID: 29792857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells.
    Yin S; Cheryan VT; Xu L; Rishi AK; Reddy KB
    PLoS One; 2017; 12(8):e0183578. PubMed ID: 28817737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.
    Wang Q; Cheng Y; Wang Y; Fan Y; Li C; Zhang Y; Wang Y; Dong Q; Ma Y; Teng YE; Qu X; Liu Y
    BMC Cancer; 2017 Jul; 17(1):492. PubMed ID: 28724364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
    Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
    Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
    Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
    Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of lovastatin- and docosahexaenoic acid-initiated autophagy in triple negative breast cancer reverted resistance and enhanced cytotoxicity.
    El-Ashmawy NE; Al-Ashmawy GM; Amr EA; Khedr EG
    Life Sci; 2020 Oct; 259():118212. PubMed ID: 32768581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in Vivo.
    Li HC; Xia ZH; Chen YF; Yang F; Feng W; Cai H; Mei Y; Jiang YM; Xu K; Feng DX
    Cell Physiol Biochem; 2017; 43(5):1829-1840. PubMed ID: 29050003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elucidation of Altered Pathways in Tumor-Initiating Cells of Triple-Negative Breast Cancer: A Useful Cell Model System for Drug Screening.
    Christensen AG; Ehmsen S; Terp MG; Batra R; Alcaraz N; Baumbach J; Noer JB; Moreira J; Leth-Larsen R; Larsen MR; Ditzel HJ
    Stem Cells; 2017 Aug; 35(8):1898-1912. PubMed ID: 28600813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer.
    Yang A; Qin S; Schulte BA; Ethier SP; Tew KD; Wang GY
    Cancer Res; 2017 Dec; 77(23):6641-6650. PubMed ID: 28951456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133
    Brugnoli F; Grassilli S; Lanuti P; Marchisio M; Al-Qassab Y; Vezzali F; Capitani S; Bertagnolo V
    BMC Cancer; 2017 Sep; 17(1):617. PubMed ID: 28870198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of Spry1 inhibits triple-negative breast cancer malignancy by decreasing EGF/EGFR mediated mesenchymal phenotype.
    He Q; Jing H; Liaw L; Gower L; Vary C; Hua S; Yang X
    Sci Rep; 2016 Mar; 6():23216. PubMed ID: 26976794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loading Lovastatin into Camptothecin-Floxuridine Conjugate Nanocapsules for Enhancing Anti-metastatic Efficacy of Cocktail Chemotherapy on Triple-negative Breast Cancer.
    Zhang N; Liang X; Gao C; Chen M; Zhou Y; Krueger CJ; Bao G; Gong Z; Dai Z
    ACS Appl Mater Interfaces; 2018 Sep; 10(35):29385-29397. PubMed ID: 30096224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.